Hepatitis Monthly

Published by: Kowsar

Hepatitis C Virus Treatment Revolution: Eastern European Story

Carol Stanciu 1 , * and Anca Trifan 1 , 2
Authors Information
1 Emergency University Hospital, Institute of Gastroenterology and Hepatology, Iasi, Romania
2 University of Medicine and Pharmacy, Iasi, Romania
Article information
  • Hepatitis Monthly: July 01, 2015, 15 (7); e28969
  • Published Online: July 22, 2015
  • Article Type: Rapid Communication
  • Received: April 1, 2015
  • Accepted: June 6, 2015
  • DOI: 10.5812/hepatmon.28969v2

To Cite: Stanciu C, Trifan A. Hepatitis C Virus Treatment Revolution: Eastern European Story, Hepat Mon. 2015 ; 15(7):e28969. doi: 10.5812/hepatmon.28969v2.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Treatment Revolution
3. The Situation in Eastern Europe
4. What Should Be Done
5. Towards Medical Triumph for All
  • 1. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989; 244(4902): 362-4[PubMed]
  • 2. Chung RT, Baumert TF. Curing chronic hepatitis C--the arc of a medical triumph. N Engl J Med. 2014; 370(17): 1576-8[DOI][PubMed]
  • 3. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HJ, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989; 321(22): 1501-6[DOI][PubMed]
  • 4. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998; 352(9138): 1426-32[PubMed]
  • 5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FJ, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82[DOI][PubMed]
  • 6. Poordad F, McCone JJ, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13): 1195-206[DOI][PubMed]
  • 7. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25): 2405-16[DOI][PubMed]
  • 8. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013; 368(1): 34-44[DOI][PubMed]
  • 9. Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology. 2012; 56(6): 2039-50[DOI][PubMed]
  • 10. Ward JW. Hepatitis C virus: the 25-year journey from discovery to cure. Hepatology. 2014; 60(5): 1479-82[DOI][PubMed]
  • 11. Pawlotsky JM. Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. Gastroenterology. 2015; 148(3): 468-79[DOI][PubMed]
  • 12. GILEAD . Chronic hepatitis C treatment expansion generic manufacturing for developing countries. 2014;
  • 13. Esmat G. Hepatitis C in the Eastern Mediterranean Region. East Mediterr Health J. 2013; 19(7): 587-8[PubMed]
  • 14. Phelan M, Cook C. A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. BMC Infect Dis. 2014; 14 Suppl 6[DOI][PubMed]
  • 15. Flick M, Hirschler B. Gilead offers Egypt new hepatitis C drug at 99 percent discount. 2014;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments